Clinical Focus Targeted oncology focus on RAF, NRAS, and FGFR-driven tumors presents BD opportunities with pharmaceutical partners seeking companion diagnostics, biomarker strategies, or co-development deals to expand reach of existing pipelines.

Strategic Moves Recent corporate actions including IPO, merger with XOMA, and asset sales to Pierre Fabre signal a flexible balance sheet and potential licensing or asset acquisition conversations to access late-stage assets or pivot to higher-value programs.

Financial Position Revenue in the mid-range and substantial overall funding suggest readiness for collaborative programs, capability expansions, or joint development arrangements to accelerate clinical timelines with partner capital.

Global Partnerships Past asset licensing and cross-border transactions indicate openness to international collaborations, enabling BD outreach to global pharma players for co- development, milestone-based deals, or technology-sharing arrangements.

Pipeline & Discovery Active discovery engine and multiple clinical programs create opportunities for strategic alliances around early-stage candidates, platform access, or data-sharing agreements to de-risk and accelerate exploration of new targets.